Abstract: Drugging the Undruggable: Targeting Transcription Factors with Small Cyclic Peptides Transcription factors such as Myc, STAT3 and HSF1 represent key targets for novel cancer therapies. Because they lack the structural features of traditional drug targets, these proteins are often classified as """"""""undruggable."""""""" This assumption is perpetuated by the fact that, despite intensive screening efforts using traditional methods, there are few known compounds that target transcription factors. However, potent natural products such as cyclosporine and rapamycin can bind diverse, non-traditional targets that would otherwise be overlooked. Cyclic peptides resemble these natural product macrocycles, and thus have the potential to target promising proteins, including transcription factors, previously dismissed as """"""""undruggable."""""""" Novel screening technologies will be required to discover bioactive cyclic peptides (CPs). We recently described a method of genetically encoding CP libraries for phenotypic selections in the yeast Saccharomyces cerevisiae. Since transcription is such a fundamental process, it is critical to perform selections in live organisms to ensure activity and selectivity for the target protein in the context of the full eukaryotic transcriptional machinery. This technique allows tens of millions of CPs to be screened in live cells in a single day without expensive robotics, and provides a rapid route for secondary testing and optimization of hits. This proposal describes application of this method to discover CPs that inhibit diverse human transcription factors implicated in cancer. This will be accomplished by: (1) engineering yeast selection strains that report on protein-protein and protein-DNA interactions of Myc, STAT3 and HSF1, (2) applying CP libraries to the selection strains to isolate molecules that selectively disrupt these interactions, and (3) elucidating the mechanisms of action of the most promising CPs at the molecular and cellular level. These experiments will provide first-in-class drug leads suitable for further development, and will also demonstrate a rapid, inexpensive approach to drug discovery for previously overlooked targets. Public Health Relevance: Despite their fundamental roles in disease biology, transcription factors have been dismissed as """"""""undruggable"""""""" due to their structural properties. This proposal outlines a general strategy for targeting these proteins for therapeutic intervention, and applies this strategy to diverse transcription factors that cause human cancer. Validation of these and other overlooked drug targets would be a true game-changer for drug development in every major disease field.
| Kamens, Alissa J; Mientkiewicz, Kaley M; Eisert, Robyn J et al. (2018) Thioether-stapled macrocyclic inhibitors of the EH domain of EHD1. Bioorg Med Chem 26:1206-1211 |
| Siegert, Timothy R; Bird, Michael J; Makwana, Kamlesh M et al. (2016) Analysis of Loops that Mediate Protein-Protein Interactions and Translation into Submicromolar Inhibitors. J Am Chem Soc 138:12876-12884 |
| Quartararo, Justin S; Eshelman, Matthew R; Peraro, Leila et al. (2014) A bicyclic peptide scaffold promotes phosphotyrosine mimicry and cellular uptake. Bioorg Med Chem 22:6387-91 |
| Gavenonis, Jason; Sheneman, Bradley A; Siegert, Timothy R et al. (2014) Comprehensive analysis of loops at protein-protein interfaces for macrocycle design. Nat Chem Biol 10:716-22 |
| Eshelman, Matthew R; Aldous, Amanda R; Neupane, Kosh P et al. (2014) Solution structure of a designed cyclic peptide ligand for nickel and copper ions. Tetrahedron 70:7651-7654 |
| Kamens, Alissa J; Eisert, Robyn J; Corlin, Tiffany et al. (2014) Structured cyclic peptides that bind the EH domain of EHD1. Biochemistry 53:4758-60 |
| Quartararo, Justin S; Wu, Pianpian; Kritzer, Joshua A (2012) Peptide bicycles that inhibit the Grb2 SH2 domain. Chembiochem 13:1490-6 |
